All In Biotech

Drug Trial Radar · NCT02145130

Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects

A Phase I, Two Armed, Open, Prospective and Multicentre Study to Evaluate the Safety of Autologous Tissue-engineered Dermal Substitutes and Dermo-epidermal Skin Substitutes for the Treatment of Large Deep Partial and Full Thickness Skin Defects in Children and Adults

Last checked: Nov 19, 2026Latest source record: Sep 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

May 2014

Primary completion

Mar 2021

Study completion Mar 2021

Sponsor

Lead sponsor
University of ZurichAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University Hospital, Zürich
First posted
May 22, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 1 year, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is the evaluation of the safety of autologous tissue-engineered dermal substitutes "denovoDerm" (first arm) and dermo-epidermal skin substitutes "denovoSkin" (second arm) transplanted onto the wound bed in children and adults.

Conditions

  • Burn Injury
  • Soft Tissue Injury
  • Skin Necrosis
  • Scars
  • Congenital Giant Nevus
  • Skin Tumors

Interventions

  • denovoDermBiological

    Transplantation of an autologous tissue-engineered dermal substitute, covered with autologous split-thickness skin

  • denovoSkinBiological

    Transplantation of autologous tissue-engineered dermo-epidermal skin substitute, no additional coverage needed

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SafetyTime frame: denovoDerm: 4-6 days and 21 days after transplantation, denovoSkin 9-11 days and 21 days after transplantation

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University Children's Hospital Zurich: denovoDerm

    Zurich, Canton of Zurich, Switzerland

  • University Children's Hospital Zurich: denovoSkin

    Zurich, Canton of Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.